What is Aetion?
Aetion, Inc. operates at the critical intersection of data science and clinical research, providing a sophisticated platform that delivers real-world evidence to life sciences organizations. By synthesizing complex data sets, the company enables rapid, transparent, and scientifically validated insights regarding treatment efficacy, healthcare costs, and patient outcomes. This analytical capability is essential for modern pharmaceutical development, commercialization strategies, and the ongoing evolution of payment innovation models. Aetion leverages decades of expertise in epidemiology to guide high-stakes decision-making, effectively bridging the gap between raw clinical data and actionable healthcare intelligence.
How much funding has Aetion raised?
Aetion has raised a total of $203.2M across 3 funding rounds:
Series A
$11.2M
Series B
$82M
Series C
$110M
Series A (2017): $11.2M with participation from Flare Capital Partners and Lakestar
Series B (2020): $82M led by Greenspring Associates, Amgen Business Development, EDBI, Flare Capital Partners, Oxeon, JJDC, and Lakestar
Series C (2021): $110M supported by New Enterprise Associates, Flare Capital Partners, B Capital Group, Foresite Capital, and Warburg Pincus
Key Investors in Aetion
Flare Capital Partners
A leading venture firm focused on healthcare technology, Flare Capital Partners collaborates with entrepreneurs to enhance clinical outcomes and reduce systemic costs through strategic innovation.
Lakestar
A prominent venture capital firm dedicated to partnering with visionary tech entrepreneurs across sectors like Deep Tech and Healthcare, providing long-term support from Seed to Growth stages.
Warburg Pincus
A global private equity firm renowned for its expertise in growth investing, leveraging decades of experience to support management teams in building sustainable, long-term success.
What's next for Aetion?
Following its recent capital injection, Aetion is well-positioned to scale its evidence-generation capabilities to meet the growing demand for data-driven healthcare solutions. The company is expected to focus on deepening its integration within the global life sciences ecosystem, potentially expanding its reach into new therapeutic areas and international markets. As the industry shifts toward value-based care, Aetion's role in providing the empirical foundation for treatment development and commercial strategy will likely become even more central. The firm remains focused on enhancing its platform's speed and transparency, ensuring that stakeholders can navigate the complexities of modern healthcare with precision and confidence.
See full Aetion company page
